Archive for the ‘Drug Recalls & Safety Notices’ category

FDA approves treatment for fat below the chin

April 29, 2015

The U.S. Food and Drug Administration today approved Kybella (deoxycholic acid), a treatment for adults with moderate-to-severe fat below the chin, known as submental fat. Using Kybella for the treatment of fat outside of the submental area is not approved and is not recommended.

FDA approves first generic Abilify to treat mental illnesses

April 28, 2015

The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.

FDA enters consent decree with Medtronic, Inc.

April 27, 2015

The U.S. Food and Drug Administration announced today the filing of a consent decree against Medtronic, Inc., and two of the company’s officers—S. Omar Ishrak and Thomas M. Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump Systems, medical devices that deliver medication to treat primary or […]

Illinois food company agrees to stop production of contaminated sprouts

April 23, 2015

On April 22, 2015, the United States District Court for the Northern District of Illinois entered a consent decree of permanent injunction against Wholesome Soy Products Inc., of Chicago, Illinois, owner Julia Trinh, and manager Paul Trinh, following multiple findings of contaminated food and environmental samples by the U.S. Food and Drug Administration.

FDA approves first-of-its-kind corneal implant to improve near vision in certain patients

April 17, 2015

The U.S. Food and Drug Administration today approved the KAMRA inlay, a device implanted in the cornea of one eye (the clear, front surface) to improve near vision in certain patients with presbyopia. It is the first implantable device for correction of near vision in patients who have not had cataract surgery.

FDA approves first generic Copaxone to treat multiple sclerosis

April 16, 2015

The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).

U.S. Marshals seize unapproved drugs from Florida distributor

April 16, 2015

At the request of the U.S. Food and Drug Administration and the U.S. Attorney for the Southern District of Florida, U.S. Marshals seized unapproved prescription drug products valued at over $1,500,000 from Stratus Pharmaceuticals, Inc., of Miami, Florida. Stratus Pharmaceuticals marketed and distributed unapproved prescription drug products that were manufactured by Sonar Products, Inc., of […]

FDA approves Corlanor to treat heart failure

April 15, 2015

The U.S. Food and Drug Administration today approved Corlanor (ivabradine) to reduce hospitalization from worsening heart failure.

FDA approves Corlanor to treat heart failure

April 15, 2015

The U.S. Food and Drug Administration today approved Corlanor (ivabradine) to reduce hospitalization from worsening heart failure.

FDA warns consumers not to use muscle growth product called Tri-Methyl Xtreme

April 13, 2015

The U.S. Food and Drug administration is warning consumers to stop using a dietary supplement for muscle growth linked to serious liver injury.

FDA approves breath test to aid in diagnosis of delayed gastric emptying

April 6, 2015

The U.S. Food and Drug Administration today approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test to aid in the diagnosis of delayed gastric emptying, known as gastroparesis.

Massachusetts dairy operation agrees to permanent injunction to prevent illegal drug residues in animals sold for food

April 3, 2015

On April 3, 2015, the U.S. District Court for the District of Massachusetts on behalf of the U.S. Food and Drug Administration has filed a consent decree of permanent injunction against Michael P. Ferry Inc., a dairy operation located in Westport, Massachusetts, and owner Michael P. Ferry after the FDA documented multiple violations of federal […]

FDA alerts health care professionals and patients not to use products from the Prescription Center pharmacy in Fayetteville, N.C.

April 2, 2015

The U.S. Food and Drug Administration is joining the North Carolina Board of Pharmacy (NC BOP) to urge health care professionals, including veterinarians, and patients not to use products made and distributed by the Prescription Center pharmacy, located at 915 Hay St., Fayetteville, North Carolina.

FDA issues final guidance on the evaluation and labeling of abuse-deterrent opioids

April 1, 2015

The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties.

FDA expands use of CoreValve System for aortic “valve-in-valve” replacement

March 30, 2015

The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.

California seafood company to cease production of adulterated fish

March 30, 2015

At the request of the U.S. Food and Drug Administration, a judge has ordered L.A. Star Seafood Company Inc., located in Los Angeles, and its owners, Sima and Sam Goldring, to halt operations until they demonstrate to the FDA that they can process food in compliance with food safety laws and regulations.

FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema

March 25, 2015

The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema.

FDA approves treatment for inhalation anthrax

March 25, 2015

The U.S. Food and Drug Administration today approved Anthrasil, Anthrax Immune Globulin Intravenous (Human), to treat patients with inhalational anthrax in combination with appropriate antibacterial drugs.

FDA approves blood pump system to help patients maintain stable heart function during certain high-risk cardiac procedures

March 23, 2015

The U.S. Food and Drug Administration today approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary […]

Home | Copyright 2008-2024 FoodandDrugRecall.org